4.5 Review

A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens

Journal

PHARMACEUTICAL RESEARCH
Volume 39, Issue 9, Pages 2119-2134

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-022-03323-w

Keywords

COVID-19; convalescent individuals; immune response; clinical trial; vaccine regimens

Funding

  1. DST-FIST grant [SR/FST/LS- I/2018/131]

Ask authors/readers for more resources

This review comprehensively discusses the immune response and prophylactic efficacy of COVID-19 vaccines, emphasizing the importance of in-depth research on vaccine efficacy and immune control mechanisms.
The transmission of SARS-CoV-2 has caused serious health crises globally. So far, 7 vaccines that are already being assessed in Phase IV clinical trials are, Comirnaty/ Pfizer; Spikevax/Moderna (m RNA vaccine); Vaxzevria or Covishield; Ad26.COV2.S; Ad5-nCoV (adenoviral vector-based vaccine); CoronaVac and BBIBP-CorV (inactivated virus vaccine). Besides, there are about 280 vaccines that are undergoing preclinical and clinical trials including Sputnik-V, Covaxin or BBV152, and NVX-CoV2373. These vaccines are being studied for their immunological responses and efficiency against COVID-19, and have been reported to demonstrate effective T and B cell responses. However, the long-lasting immunity of these vaccine regimens still needs to be investigated. An in-depth understanding of the vaccine efficacy and immune control mechanism is imperative for the rational purposing and implementation of the vaccines. Hence, in this review, we have comprehensively discussed the immune response induced in COVID-19 patients, as well as in the convalescent individuals to avoid reinfection. Moreover, we have also summarized the immunological responses and prophylactic efficacy of various COVID-19 vaccine regimens. In this context, this review can give insights into the development of effective vaccines against SARS-CoV-2 and its variants in the future.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available